Abstract
Tumor cells often become resistant to DNA damage-based therapy; however, the underlying mechanisms are not yet understood. Here, we show that tumor cells exposed to DNA damage counteract cell death by releasing the antiapoptotic protein, survivin, from mitochondria. This is independent of p53, and requires activated checkpoint kinase 2 (Chk2), a putative tumor suppressor. Molecular or genetic targeting of Chk2 prevents the release of survivin from mitochondria, enhances DNA damage-induced tumor cell apoptosis, and inhibits the growth of resistant in vivo tumors. Therefore, activated Chk2 circumvents its own tumor-suppressive functions by promoting tumor cell survival. Inhibiting Chk2 in combination with DNA-damaging agents may provide a rational approach for treating resistant tumors.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 11576-11579 |
| Number of pages | 4 |
| Journal | Cancer Research |
| Volume | 66 |
| Issue number | 24 |
| DOIs | |
| State | Published - Dec 15 2006 |
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research